The Motley Fool

5 Things You May Not Know About Pay At GlaxoSmithKline plc

GlaxoSmithKlineExecutive pay continues to rankle many shareholders. So I’m reading the remuneration reports of leading FTSE 100 companies to help you decide whether your investments are being run by herd of ‘fat cats’. I’ve just looked at the 2013 annual report of GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) and here’s what I discovered:

1) The chief executive of GSK has during the past five years earned anywhere between £4.6m and £7.2m including all benefits. In contrast, the average GSK staff member in 2013 earned almost £63,000. The boss’s base salary was increased by 2.5% last year, while other employees enjoyed an average 2.7% pay rise. You may like to know the chief exec claimed travel expenses of £35,960 last year as well.

5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!

According to one leading industry firm, the 5G boom could create a global industry worth US$12.3 TRILLION out of thin air…

And if you click here we’ll show you something that could be key to unlocking 5G’s full potential...

2) Boardroom pay policies for 2014 could see the chief exec collect a minimum total remuneration of £2m and a maximum of £11.6m. Plus, his base pay will once again advance by 2.5% to £1.1m.

3) The company’s three executive directors collected an aggregate £14m in 2013, and senior managers at GSK took home a combined £23m between them.

4) Some £2.1m was paid by GSK as fees to no less than 13 non-executive directors last year. The same non-execs also collected a further £583,000 as benefits, which covered travel and subsistence costs relating to board and committee meetings and other GSK-hosted events.

5) GSK distributed about £3.7bn as dividends during 2013 (down 3.5%), compared to £7.6bn paid to staff (up 9.5%). The chief exec owns 734,000 ordinary shares, which last year delivered an annual dividend income of about £572,000 – some 46% less than his basic pay.

During the AGM in May, shareholders approved GSK’s remuneration report with a 98.5% vote and approved the directors’ remuneration policy with a 97.4% vote.

Of course, whether GSK’s senior directors are truly worth their wage slips – or are simply trousering the company’s cash at your expense – is something only you can decide.

“This Stock Could Be Like Buying Amazon in 1997”

I'm sure you'll agree that's quite the statement from Motley Fool Co-Founder Tom Gardner.

But since our US analyst team first recommended shares in this unique tech stock back in 2016, the value has soared.

What's more, we firmly believe there's still plenty of upside in its future. In fact, even throughout the current coronavirus crisis, its performance has been beating Wall St expectations.

And right now, we're giving you a chance to discover exactly what has got our analysts all fired up about this niche industry phenomenon, in our FREE special report, A Top US Share From The Motley Fool.

Click here to claim your copy now — and we’ll tell you the name of this Top US Share… free of charge!

Maynard Paton has no position in any shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

Our 6 'Best Buys Now' Shares

Renowned stock-picker Mark Rogers and his analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.

So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we're offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our 'no quibbles' 30-day subscription fee refund guarantee.

Simply click below to discover how you can take advantage of this.